SCHEMBL5481062

SCHEMBL5481062

COC(C(=O)Nc1ccc(CC(=O)Nc2ncc(C(C)C)s2)cc1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.69
CCNE1 P24864 12/20 0.69
CDK5 Q00535 12/20 0.69
ALDH1A1 P00352 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
CCNT1 O60563 1/20 0.69
CDK1 P06493 1/20 0.69
CDK4 P11802 1/20 0.69
CCNB1 P14635 1/20 0.69
CCNA2 P20248 1/20 0.69
CCND1 P24385 1/20 0.69
CDK7 P50613 1/20 0.69
CDK9 P50750 1/20 0.69
CCNH P51946 1/20 0.69
MNAT1 P51948 1/20 0.69
CDK5R1 Q15078 1/20 0.69
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KLK7 P49862 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476972 0.86 CDK2 (0.88) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835593 0.85 CDK2 (0.62) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835592 0.85 CDK2 (0.62) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835588 0.85 CDK2 (0.62) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL1535301 0.83 CCNE1 (1.00) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5726464 0.82 CDK2 (0.72) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5481693 0.81 CDK2 (0.67) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5480558 0.81 CDK2 (0.73) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835975 0.81 CCNE1 (0.86) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5726471 0.80 CDK2 (0.72) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3071576-B9 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL INC (US) 2021-12-22 EP claimed
EP-3071576-B1 PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS TRANSITIONS OPTICAL INC (US) 2021-08-18 EP claimed
EP-2047305-B1 ORIENTED POLYMERIC SHEETS EXHIBITING DICHROISM AND ARTICLES CONTAINING THE SAME TRANSITIONS OPTICAL INC (US) 2019-11-20 EP claimed
EP-2651911-B9 LACTONE COMPOUNDS AND MATERIALS MADE THEREFROM TRANSITIONS OPTICAL INC (US) 2019-07-17 EP claimed
EP-2970760-B1 PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS TRANSITIONS OPTICAL INC (US) 2019-06-26 EP claimed
EP-2651911-B1 LACTONE COMPOUNDS AND MATERIALS MADE THEREFROM TRANSITIONS OPTICAL INC (US) 2019-02-20 EP claimed
EP-2078006-B1 PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES TRANSITIONS OPTICAL INC (US) 2018-11-07 EP claimed
EP-2360224-B1 Photochromic compounds TRANSITIONS OPTICAL INC (US) 2018-10-17 EP claimed
EP-2970326-B1 SUBSTITUTED 5,6-RING-FUSED NAPHTHOPYRAN COMPOUNDS TRANSITIONS OPTICAL INC (US) 2017-11-29 EP claimed
EP-2651913-B1 INDENO-FUSED RING COMPOUNDS HAVING PHOTOCHROMIC PROPERTIES TRANSITIONS OPTICAL INC (US) 2017-04-19 EP claimed
EP-1626046-B1 Photochromic oxazine compounds and methods for their manufacture ESSILOR INT (FR) 2014-11-19 EP claimed
EP-1204649-B1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-10-17 EP claimed
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA ITALIS S.P.A. (IT) 2005-01-06 US claimed
EP-1214311-B1 NOVEL INDENO-FUSED PHOTOCHROMIC NAPHTHOPYRANS TRANSITIONS OPTICAL INC (US) 2004-09-15 EP claimed
US-6784198-B1 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA ITALIA S.P.A. (IT) 2004-08-31 US claimed
CN-1425009-A Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-06-18 CN claimed
EP-1204649-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2002-05-15 EP claimed
WO-2001014353-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA, S.P.A. (IT) 2001-03-01 WO claimed
US-6114365-A Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2000-09-05 US claimed
US-4758559-A Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors CIBA-GEIGY CORPORATION (US) 1988-07-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents CCAR2, BCL2, ROS1 CDK2 26/4885CCNE1 513/4885CDK5 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.